Dermata Therapeutics, Inc. (DRMA)
| Market Cap | 3.39M +45.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.37M |
| EPS | -3.33 |
| Shares Out | 4.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,357 |
| Open | 0.8444 |
| Previous Close | 0.8487 |
| Day's Range | 0.8032 - 0.8696 |
| 52-Week Range | 0.6032 - 4.6600 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 17, 2026 |
About DRMA
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsNews
Dermata initiates acne clinical trial of second Tome skincare product
Dermata Therapeutics (DRMA) announced enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the company’s once-weekly acne treatment, in participants with acne. T...
Dermata announces results from study evaluating Tome Foundational Treatment
Dermata Therapeutics (DRMA) announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company’s recently launched once-weekly s...
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments - - Over 71% of study participants were graded as having overall improv...
Dermata Therapeutics registers to sell 6.92M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.92M shares of common stock. The company is not selling any…
Dermata Therapeutics Registration statement: Registration filing
Dermata Therapeutics filed a registration statement on October 9, 2026, providing details about a securities offering with the SEC.
Dermata Therapeutics announces commercial launch of Tome Foundational Treatment
Dermata Therapeutics (DRMA) announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company’s Tome skincare brand. The Foundatio...
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com - - Once-weekly Foundational Treatment is designed to renew the appearance of skin and impro...
Dermata Therapeutics announces Tome Foundational Treatment open to preorders
Dermata Therapeutics (DRMA) announced that Tome Foundational Treatment, the Company’s first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected t...
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
- Preorders can be made by visiting www.tomeskincare.com - - Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 - - Tome Foundational Treatment is a once-weekly t...
Dermata Therapeutics prices 2.29M shares at $1.46 in private placement
Dermata Therapeutics (DRMA) entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock, series E warrants to purchase up to 2,293,608 shares…
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Ther...
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Veg...
Dermata Therapeutics Earnings release: Q2 2026
Dermata Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Dermata Therapeutics Quarterly report: Q2 2026
Dermata Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Dermata to commercially launch Tome Foundational Treatment on August 25
Dermata Therapeutics (DRMA) announced that Tome Foundational Treatment, the Company’s first direct-to-consumer skincare product, is planned to launch on August 25, 2026, with those on the waitlist get...
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch, planned for August 25, 2026 - - Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newsw...
Dermata Therapeutics Registration statement: Registration filing
Dermata Therapeutics filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to...
Dermata Therapeutics Quarterly report: Q1 2026
Dermata Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Dermata Therapeutics Earnings release: Q1 2026
Dermata Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Dermata Therapeutics Proxy statement: Proxy filing
Dermata Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dermata Therapeutics Proxy statement: Proxy filing
Dermata Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dermata Therapeutics Proxy statement: Proxy filing
Dermata Therapeutics filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Dermata receives notice of acceptance of Australian patent application
Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled “Compositions for t...
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers - - The Company also has allowed and issued patents in the US, Australi...